Drug intelligence / Profile preview

SCTB39G

Development stage: Phase 2
Lead developer: Sinocelltech
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**SCTB39G** is an investigational trispecific antibody developed for the intravenous treatment of advanced malignant solid tumors. It is currently being assessed as a monotherapy to evaluate its safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor efficacy in adult patients with advanced solid cancers. The molecule is in Phase I/II clinical trials, using a dose-escalation and dose-expansion design. SCTB39G is a biologic modality engineered to bind to three distinct targets, although the specific targets and detailed mechanism of action have not been publicly disclosed[1][2][3][4][6][8].

Brand names: SCTB39GSCTB-39GSCTB 39G
Other names: SCTB39GSCTB-39GSCTB 39G

Beyond the preview

Go deeper on SCTB39G.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCTB39G.

Explore the full profile